134575-15-8

Usage

Uses

Used in Medicinal Chemistry:
Exo-3-Cbz-3-azabicyclo[3.1.0]hexane-6-carboxylic acid is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with distinct biological activities, contributing to the advancement of medicinal chemistry.
Used in Drug Development:
In the pharmaceutical industry, exo-3-Cbz-3-azabicyclo[3.1.0]hexane-6-carboxylic acid is employed as a building block for designing and optimizing drug candidates. Its specific properties and reactivity can be leveraged to create novel therapeutic agents with improved efficacy and selectivity.
Used in Chemical Research:
Exo-3-Cbz-3-azabicyclo[3.1.0]hexane-6-carboxylic acid serves as a subject of study in chemical research, where its synthesis and characterization can provide insights into the behavior of complex organic molecules. Understanding its properties and reactivity can contribute to the development of new synthetic methods and strategies in organic chemistry.
Used in Biochemical Studies:
Due to its potential biological activities, exo-3-Cbz-3-azabicyclo[3.1.0]hexane-6-carboxylic acid is used in biochemical studies to explore its interactions with biological targets, such as enzymes, receptors, or other macromolecules. This research can lead to the discovery of new pharmacological agents with specific therapeutic applications.

Upstream product

• 5041-33-8 N-(Benzyloxycarbonyl)allylamine 
• 479672-17-8 (E)-methyl 4-(((benzyloxy)carbonyl)amino)but-2-enoate 
• 174456-77-0 [(1α,5α,6α)-3-aza-bicyclo[3.1.0]hexane]-6-carboxylic acid ethyl ester 
• 146726-10-5 3-benzyl 6-ethyl (1α,5α,6α)-3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate 
• 75-09-2 dichloromethane 
• 134575-06-7 ethyl (1α,5α,6α)-3-benzyl-3-azabicyclo[3.1.0]hexane-2,4-dione-6-carboxylate 
• 134575-07-8 (1α,5α,6α)-6-hydroxymethyl-3-benzyl-3-aza-bicyclo[3.1.0]hexane 
• 134575-13-6 (1α,5α,6α)-6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane 
• 31970-04-4 1-carboxybenzyl-3-pyrrolidine 
• 134575-14-7 benzyl (1α,5α,6α)-6-hydroxymethyl-3-azabicyclo[3.1.0]hexan-3-ylcarboxylate 

Downstream Products

• 134575-14-7 benzyl (1α,5α,6α)-6-hydroxymethyl-3-azabicyclo[3.1.0]hexan-3-ylcarboxylate 
• 925457-08-5 1-(2,4-difluorophenyl)-7-[(1α,5α,6α)-6-[[(1,1-dimethylethoxy)carbonyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid 
• 134575-17-0 tert-butyl (1R,5S,6R)-3-azabicyclo[3.1.0]hexan-6-ylcarbamate 
• 146726-08-1 (1α,5α,6α)-6-tert-butoxycarbonylamino-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

Efficient synthesis of cyclopropane-fused heterocycles with bromoethylsulfonium salt

Lord of the rings! [3.1.0] bicyclic ring systems were synthesized using bromoethylsulfonium triflate and easily available amino acid/aza-Morita-Baylis- Hillman-derived allylic amines. The simple transformation displays a very high degree of diastereoselec

INDOLE DERIVATIVES USEFUL AS CCR2 ANTAGONISTS

Disclosed are the CCR2 antagonists of Formula I: I or pharmaceutically acceptable salt thereof wherein R7, A, X, B, and n are defined herein. Also disclosed are pharmaceutical compositions containing the compounds, methods of treatment using the compounds

SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES USEFUL AS CCR2 ANTAGONISTS

Disclosed are CCR2 antagonists of Formula (I)or pharmaceutically acceptable thereof, wherein R1, L1 and A are defined herein. Also disclosed are pharmaceutical compositions containing the compounds, methods of treatment using the compounds, and compositions to treat diseases or disorders associated with CCR2 activity.

6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES

The present invention relates to 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

Conformational constraint in oxazolidinone antibacterials. Synthesis and structure-activity studies of (azabicyclo[3.1.0]hexylphenyl)oxazolidinones

The oxazolidinones are a new class of synthetic antibacterials effective against a broad range of pathogenic Gram-positive bacteria, including multi-drug-resistant strains. Linezolid is the first drug from this class to reach the market and has become an

ANTIMICROBIAL [3.1.0] BICYCLIC OXAZOLIDINONE DERIVATIVES

The present invention provides certain [3.1.0] bicyclic oxazolidinone derivatives of Formulea I and II, described herein, or pharmaceutically acceptable salts or prodrugs thereof that are antibacterial agents, pharmaceutical compositions containing them,

Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.

The synthesis of four new computer-designed fluoroquinolones which have been predicted by QSAR analysis to be active against the protozoa Toxoplasma gondii is described. These compounds are inhibitory in vitro for T. gondii. One of these compounds has a remarkably high activity comparable to that of trovafloxacin. It combines the basic cyclopropyl-quinoline structure of gatifloxacin or moxifloxacin with the C-7 6-amino-3-azabicyclo[3.1.0]hexyl side chain of trovafloxacin. The four compounds are also inhibitory for blood stages of Plasmodium falciparum though at high concentration. These results confirm the potential of quinolones as anti-T. gondii and antimalarial drugs but also show that the QSAR models for T. gondii cannot be reliably extended for screening antimalarial activity.

Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones

This invention relates to certain azabicyclo hexane intermediates and processes for making and using the azabicyclo hexane intermediates. The intermediates are useful in the synthesis of quinolone antibacterial agents.

Azabicyclo quinolone carboxylic acids

Quinolone carboxylic acids 7-substituted by azabicyclo groups have antibacterial activity., Antibacterial wherein, R1 is hydrogen, a pharmaceutically acceptable cation, or alkyl;, Y, when taken independently, is ethyl, t-butyl, vinyl, cyclopropyl, 2-fluoroethyl, p-fluorophenyl, or o,p-difluorophenyl;, W is hydrogen, F, Cl, Br, alkyl, alkoxy, NH2, NHCH3;, A is CH, CF, CCl, COCH3, C-CH3, C-CN or N; or, A is carbon and is taken together with Y and the carbon and nitrogen to which A and Y are attached to form a five or six membered ring which may contain oxygen or a double bond, and which may have attached thereto R8 which is methyl or methylene; and, R2 is wherein R3, R4, R5, R6, R7, R9, R10 and R25 are each independently H, CH3, CH2NH2, CH2NHCH3 or CH2NHC2H5, and R5, R6, R7, and R9 may also independently be NH2, NHCH3 or NHC2H5.